Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 253 |
| Active Pipeline (Recruiting Now) | 131 (87) |
| Completed vs Stopped Early | 74 / 48 (19.0%) |
| Median Closed Actual Enrollment | 27 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Mayo Clinic Rochester | Rochester, MN | 193 |
| Mayo Clinic Florida | Jacksonville, FL | 76 |
| Mayo Clinic Arizona | Phoenix, AZ | 65 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06028022 | Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors | Phase II | RECRUITING |
| NCT06395441 | Wisconsin Ginseng for Decreasing Cancer Related Fatigue | Phase III | RECRUITING |
| NCT07100990 | Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Mayo Clinic across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Mayo Clinic Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.